Wide occurrence of aortic stenosis to boost transcatheter aortic valve replacement demand
Category: #health  By Pankaj Singh  Date: 2021-01-11
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Wide occurrence of aortic stenosis to boost transcatheter aortic valve replacement demand

Research and development in the global transcatheter heart valve replacement industry have been gathering pace in recent years, with the increasing occurrence of valvular heart diseases and the demand for less invasive surgical procedures.

Transcatheter heart valve replacement is a minimally invasive procedure used to treat aortic valve stenosis, a condition which is caused by factors such as age, high cholesterol, high blood pressure, and excessive smoking. The procedure has emerged as a promising option for patients who are at an intermediate of high risk of complications through open-heart surgery. It can help alleviate the signs and symptoms of aortic valve stenosis and improve survival in patients with severe symptoms.

Reports estimate that the global transcatheter heart valve replacement market size will reach an annual valuation of nearly US$19.5 billion by the year 2026, with constant research and development in the field.

In recent years, a number of successful transcatheter aortic valve replacement (TAVR) procedures have been conducted around the world. With the growing preference of consumers towards less invasive surgical options, leading players in the market are focusing on developing novel TAVR solutions.

In January 2021, Shanghai-based DeltaHealth Hospital had conducted the city’s first transcatheter heart valve replacement in a 71-year-old female patient with aortic valve stenosis. The procedure was carried out using the next-generation valve replacement system Sapien 3 designed by US-based Edwards Lifesciences Corporation. This is the first instance where Sapien 3 has been used in surgery in Shanghai since its approval in China.

The Sapien 3 has been approved for patients who are at high risk or unable to undergo an open-heart valve replacement surgery due to physical condition, age, or other factors. It is designed to replacement an individual’s damaged aortic valve via a minimally invasive procedure. It can be used to provide patients suffering from severe aortic valve stenosis with the option of a shorter procedure with promising clinical outcomes, along with faster recovery compared to conventional open-heart surgery.

Earlier in June 2020, the Edwards Sapien 3 transcatheter heart valve had received Chinese regulatory approval for the treatment of patients with severe, symptomatic aortic valve stenosis.

Numerous research trials have also been conducted during the ongoing COVID-19 pandemic which has put healthcare systems under enormous strain over the past few months, resulting in the suspension of most elective procedures, including TAVR. However, the deferment of TAVR could lead to considerable wait-time mortality in patients suffering from severe aortic valve stenosis. On the contrary, there is currently limited data available regarding the safety, reliability, and feasibility of a continued PAVR procedure during the coronavirus crisis.

A study conducted between February and June 2020 has shown that a continued TAVR program during the ongoing unprecedented crisis could be feasible despite the availability of limited hospital resources. The COVID-19 related mortality following the procedure, however, could be a major concern.

 

The industry players still need to tackle numerous challenges including the high cost and risk associated with transcatheter heart valve replacement as well as strict government regulations. Ongoing technological advances and R&D programs to overcome these challenges will certainly bolster the overall transcatheter heart valve replacement industry outlook.

Abbott, 4C Medical Technologies, Boston Scientific Corporation, Micro Interventional Devices, Medtronic Plc, JC Medical, and Edward Lifesciences are currently among the notable names in the industry.

 



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

PCS Software adds new contactless features to expand TMS platform

PCS Software adds new contactless features to expand TMS platform

By Pankaj Singh

  • With this addition, it is now possible for PCS consumers to effectively manage their workflows using their mobile devices
  • Document digitization has...

ODP teams up with Microsoft to support shared & new B2B customers

ODP teams up with Microsoft to support shared & new B2B customers

By Pankaj Singh

The ODP Corporation, an American retail company, has recently announced the expansion of its long-standing relationship with Microsoft. The two companies are planning to boost efficiencies and growth of their shared as...

Gannex reveals positive data from ASC41 clinical study in 20 subjects

Gannex reveals positive data from ASC41 clinical study in 20 subjects

By Pankaj Singh

Ascletis Pharma Inc.’s wholly-owned company, Gannex, has reportedly announced the positive clinical data from its ASC41 trial conducted among overweight and obese subjects. The active metabolite of this liver-tar...